Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1987 Jan;55(1):67–73. doi: 10.1038/bjc.1987.14

Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases.

M R Williams, J H Todd, I O Ellis, C S Dowle, J L Haybittle, C W Elston, R I Nicholson, K Griffiths, R W Blamey
PMCID: PMC2001565  PMID: 3814477

Abstract

ER content of primary tumour tissue has been examined in 704 patients presenting with operable breast cancer. The median follow-up is now 84 months and no patient has received adjuvant therapy of any kind. ER status is related to histological grade, menopausal status, initial site of metastases and subsequent response to endocrine therapy. A significant advantage in terms of survival is found in ER positive patients which is confined to those lymph node positive at mastectomy. DFI is also significantly related to ER status in lymph node positive patients. Survival after the symptomatic presentation of metastases and the institution of endocrine therapy is prolonged in patients with ER positive tumours. The overall response rate to endocrine therapy in assessable patients with ER positive tumours is 32%. By combining the ER status and histological grade of tumour tissue, a group of patients comprising 28% of those assessable to endocrine therapy can be identified (ER positive, grade I and II) with a response rate of 46%.

Full text

PDF
67

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aamdal S., Børmer O., Jørgensen O., Høst H., Eliassen G., Kaalhus O., Pihl A. Estrogen receptors and long-term prognosis in breast cancer. Cancer. 1984 Jun 1;53(11):2525–2529. doi: 10.1002/1097-0142(19840601)53:11<2525::aid-cncr2820531126>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  2. Alanko A., Heinonen E., Scheinin T. M., Tolppanen E. M., Vihko R. Oestrogen and progesterone receptors and disease-free interval in primary breast cancer. Br J Cancer. 1984 Nov;50(5):667–672. doi: 10.1038/bjc.1984.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Allegra J. C., Lippman M. E., Simon R., Thompson E. B., Barlock A., Green L., Huff K. K., Do H. M., Aitken S. C., Warren R. Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep. 1979 Aug;63(8):1271–1277. [PubMed] [Google Scholar]
  4. Allegra J. C., Lippman M. E., Thompson E. B., Simon R., Barlock A., Green L., Huff K. K., Do H. M., Aitken S. C., Warren R. Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer. Eur J Cancer. 1980 Mar;16(3):323–331. doi: 10.1016/0014-2964(80)90348-5. [DOI] [PubMed] [Google Scholar]
  5. Bishop H. M., Blamey R. W., Elston C. W., Haybittle J. L., Nicholson R. I., Griffiths K. Relationship of oestrogen-receptor status to survival in breast cancer. Lancet. 1979 Aug 11;2(8137):283–284. doi: 10.1016/s0140-6736(79)90295-2. [DOI] [PubMed] [Google Scholar]
  6. Blamey R. W., Bishop H. M., Blake J. R., Doyle P. J., Elston C. W., Haybittle J. L., Nicholson R. I., Griffiths K. Relationship between primary breast tumor receptor status and patient survival. Cancer. 1980 Dec 15;46(12 Suppl):2765–2769. doi: 10.1002/1097-0142(19801215)46:12+<2765::aid-cncr2820461404>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  7. Caldarola L., Calderini P., Volterrani P., Di Carlo F., Gaglia P. The correlation between estrogen receptor status, axillary-node metastases and disease-free interval after surgery in primary breast cancer. Ital J Surg Sci. 1983;13(3):179–185. [PubMed] [Google Scholar]
  8. Campbell F. C., Blamey R. W., Elston C. W., Nicholson R. I., Griffiths K., Haybittle J. L. Oestrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer. 1981 Sep;44(3):456–459. doi: 10.1038/bjc.1981.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cant E. M., Horsfall D., Keightley D. D. Value of hormone receptors in the management of breast cancer--I. Advanced breast cancer. Aust N Z J Surg. 1985 Apr;55(2):121–125. doi: 10.1111/j.1445-2197.1985.tb00870.x. [DOI] [PubMed] [Google Scholar]
  10. Cooke T., George D., Shields R., Maynard P., Griffiths K. Oestrogen receptors and prognosis in early breast cancer. Lancet. 1979 May 12;1(8124):995–997. doi: 10.1016/s0140-6736(79)92752-1. [DOI] [PubMed] [Google Scholar]
  11. Haybittle J. L., Blamey R. W., Elston C. W., Johnson J., Doyle P. J., Campbell F. C., Nicholson R. I., Griffiths K. A prognostic index in primary breast cancer. Br J Cancer. 1982 Mar;45(3):361–366. doi: 10.1038/bjc.1982.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  13. Hilf R., Feldstein M. L., Gibson S. L., Savlov E. D. The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer. 1980 Apr 15;45(8):1993–2000. doi: 10.1002/1097-0142(19800415)45:8<1993::aid-cncr2820450802>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  14. Howat J. M., Harris M., Swindell R., Barnes D. M. The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer. 1985 Feb;51(2):263–270. doi: 10.1038/bjc.1985.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Howell A., Barnes D. M., Harland R. N., Redford J., Bramwell V. H., Wilkinson M. J., Swindell R., Crowther D., Sellwood R. A. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet. 1984 Mar 17;1(8377):588–591. doi: 10.1016/s0140-6736(84)90995-4. [DOI] [PubMed] [Google Scholar]
  16. Kinne D. W., Ashikari R., Butler A., Menendez-Botet C., Rosen P. P., Schwartz M. Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer. 1981 May 15;47(10):2364–2367. doi: 10.1002/1097-0142(19810515)47:10<2364::aid-cncr2820471007>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  17. Knight W. A., Livingston R. B., Gregory E. J., McGuire W. L. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977 Dec;37(12):4669–4671. [PubMed] [Google Scholar]
  18. Masters J. R., Millis R. R., Rubens R. D. Response to endocrine therapy and breast cancer differentiation. Breast Cancer Res Treat. 1986;7(1):31–34. doi: 10.1007/BF01886733. [DOI] [PubMed] [Google Scholar]
  19. Maynard P. V., Blamey R. W., Elston C. W., Haybittle J. L., Griffiths K. Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res. 1978 Nov;38(11 Pt 2):4292–4295. [PubMed] [Google Scholar]
  20. Maynard P. V., Davies C. J., Blamey R. W., Elston C. W., Johnson J., Griffiths K. Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer. 1978 Dec;38(6):745–748. doi: 10.1038/bjc.1978.282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Millis R. R., Rubens R. D., Masters J. R., Minton M. J. Histological grade and response to endocrine therapy in breast cancer. Lancet. 1981 Jul 11;2(8237):101–101. doi: 10.1016/s0140-6736(81)90459-1. [DOI] [PubMed] [Google Scholar]
  22. Neifeld J. P., Lawrence W., Jr, Brown P. W., Banks W. L., Terz J. J. Estrogen receptors in primary breast cancer. Arch Surg. 1982 Jun;117(6):753–757. doi: 10.1001/archsurg.1982.01380300001001. [DOI] [PubMed] [Google Scholar]
  23. Nicholson R. I., Campbell F. C., Blamey R. W., Elston C. W., George D., Griffiths K. Steroid receptors in early breast cancer: value in prognosis. J Steroid Biochem. 1981 Dec;15:193–199. doi: 10.1016/0022-4731(81)90275-2. [DOI] [PubMed] [Google Scholar]
  24. Osborne C. K., Yochmowitz M. G., Knight W. A., 3rd, McGuire W. L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2884–2888. doi: 10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  25. Parl F. F., Schmidt B. P., Dupont W. D., Wagner R. K. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer. 1984 Nov 15;54(10):2237–2242. doi: 10.1002/1097-0142(19841115)54:10<2237::aid-cncr2820541029>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  26. Paterson A. H., Zuck V. P., Szafran O., Lees A. W., Hanson J. Influence and significance of certain prognostic factors on survival in breast cancer. Eur J Cancer Clin Oncol. 1982 Oct;18(10):937–943. doi: 10.1016/0277-5379(82)90241-3. [DOI] [PubMed] [Google Scholar]
  27. Raemaekers J. M., Beex L. V., Koenders A. J., Pieters G. F., Smals A. G., Benraad T. J., Kloppenborg P. W. Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res Treat. 1985;6(2):123–130. doi: 10.1007/BF02235743. [DOI] [PubMed] [Google Scholar]
  28. Roberts M. M., Rubens R. D., King R. J., Hawkins R. A., Millis R. R., Hayward J. L., Forrest A. P. Oestrogen receptors and the response to endocrine therapy in advanced breast cancer. Br J Cancer. 1978 Sep;38(3):431–436. doi: 10.1038/bjc.1978.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Samaan N. A., Buzdar A. U., Aldinger K. A., Schultz P. N., Yang K. P., Romsdahl M. M., Martin R. Estrogen receptor: a prognostic factor in breast cancer. Cancer. 1981 Feb 1;47(3):554–560. doi: 10.1002/1097-0142(19810201)47:3<554::aid-cncr2820470322>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES